BIOT

•

Equity

L&G PHARMA BREAKTHROUGH UCITS ETF

TER (bps):

49

AUM (USD m):

18

ISIN:

IE00BF0H7608

Domicile:

Ireland

Share Class Currency:

USD

ESG:

No

Geographical Focus:

Global

As of:

03 Oct 2024

Climate Fund:

No

Benchmark

The Solactive Pharma Breakthrough Value Index aims to track the performance of a basket of stocks of companies that are actively engaged in the research, development and/or manufacturing of orphan drugs. it uses a two-fold approach that is primarily based on the trend in the valuation of a company’s orphan drug portfolio and its overall revenue forecasts. The Index selects stocks that meet certain size and liquidity requirements.

PERFORMANCE

Powered byhttps://www.etfbook.com/ logo

RELATED ARTICLES

graphical user interface
Analysis

Thematic ETFs: Analysing performance drivers in 2021

The 12-month performance gap between the top and bottom ETFs on our list is 77.3%

Jamie Gordon

a man smiling for the picture
New Listing

LGIM launches Europe’s first digital payments ETF

PDAY tracks the Solactive Digital Payments index

Jamie Gordon

a man smiling for the picture
New Listing

LGIM launches Europe’s first hydrogen economy ETF

Tom Eckett

MOST READ

1
New Listing

BlackRock extends range of US equity ETFs with double launch

Toby Lawes

2
Industry Updates

BlackRock’s S&P 500 ETF: Europe’s first to $100bn

Toby Lawes

3
New Listing

BlackRock unveils lithium and battery producers ETF

Jamie Gordon

4
Industry Updates

ARK Invest teams up with eToro to launch portfolio of ETFs

Lauren Gibbons

5
Analysis

Where next for fixed maturity ETFs?

Lauren Gibbons